Processa Pharmaceuticals Amends 10-K to Detail $1.4M Capital Raises and Executive Compensation
PCSA sits 53% above its 52-week low of $1.76 on light trading volume (0.2× avg).
Summary
Processa Pharmaceuticals filed an amended annual report (10-K/A) to include previously omitted information regarding executive compensation, beneficial ownership, and significant capital raises totaling $1.4 million from The Chiliz Group.
Key Events · Corporate Governance and Compliance · PCSA
-
Details $1.4 Million in Capital Raises
The amendment discloses that the company sold 218,688 shares for $1.2 million in net proceeds to The Chiliz Group on August 4, 2025, and an additional 86,956 shares for $200,000 on February 17, 2026. These transactions provide significant funding for the company.
-
Executive Officer Transition
Dr. Sian Bigora, Chief Development and Regulatory Officer, will transition from a full-time executive role to a part-time employee position effective May 1, 2026, and will no longer be designated an executive officer.
-
Comprehensive Compensation Disclosure
The filing includes detailed executive and director compensation for the fiscal year ended December 31, 2025, outlining salaries, bonuses, and equity awards for key personnel.
-
Updated Beneficial Ownership Information
The report provides updated beneficial ownership data as of April 29, 2026, identifying The Chiliz Group as an 11.2% owner and Mitchell Kopin, Daniel Asher, and Intracoastal Capital, LLC as 7.3% owners. Officers and directors collectively own 2.8%.
Analysis · PCSA · Life Sciences
This 10-K/A filing provides crucial missing information from the original annual report, offering investors a more complete financial and operational picture. The disclosure of $1.4 million in capital raises from The Chiliz Group, while historical, is significant for a company of this size, providing insight into its funding strategy and potential dilution. The detailed executive and director compensation, along with beneficial ownership information, enhances transparency. The transition of a key executive to a part-time role is a minor organizational change. Overall, this amendment addresses compliance gaps and offers important retrospective financial context.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSA was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $1.76 to $19.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.